Amalgamated Bank Has $187,000 Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Amalgamated Bank reduced its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 9.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,706 shares of the biopharmaceutical company’s stock after selling 467 shares during the quarter. Amalgamated Bank’s holdings in Celldex Therapeutics were worth $187,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its stake in shares of Celldex Therapeutics by 1.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 164,157 shares of the biopharmaceutical company’s stock valued at $4,518,000 after buying an additional 2,408 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Celldex Therapeutics by 36.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,582 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 1,746 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Celldex Therapeutics by 70.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 805 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Celldex Therapeutics by 4.8% in the 3rd quarter. Teacher Retirement System of Texas now owns 11,400 shares of the biopharmaceutical company’s stock valued at $314,000 after purchasing an additional 522 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Celldex Therapeutics by 13.2% in the 3rd quarter. Principal Financial Group Inc. now owns 12,848 shares of the biopharmaceutical company’s stock valued at $354,000 after purchasing an additional 1,497 shares during the last quarter.

Celldex Therapeutics Stock Performance

Shares of CLDX stock opened at $38.10 on Thursday. The company has a market capitalization of $2.51 billion, a P/E ratio of -13.37 and a beta of 1.60. The company’s 50 day moving average price is $39.92 and its two-hundred day moving average price is $38.11. Celldex Therapeutics, Inc. has a 52 week low of $22.11 and a 52 week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.19. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. The company had revenue of $4.13 million for the quarter, compared to the consensus estimate of $1.20 million. Analysts forecast that Celldex Therapeutics, Inc. will post -2.32 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on CLDX. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, May 15th. Guggenheim lifted their price objective on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Friday, March 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $66.00.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.